PMID- 20051949
OWN - NLM
STAT- MEDLINE
DCOM- 20100223
LR  - 20231115
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Print)
IS  - 0007-0920 (Linking)
VI  - 102
IP  - 3
DP  - 2010 Feb 2
TI  - Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic 
      cancer.
PG  - 577-82
LID - 10.1038/sj.bjc.6605494 [doi]
AB  - BACKGROUND: Enzyme-linked immunoassays of full-length (M65) and/or 
      caspase-cleaved (M30) cytokeratin 18 (CK18) released from epithelial cells 
      undergoing necrosis and/or apoptosis, respectively, may have prognostic or 
      predictive biomarker utility in a range of solid tumour types. Characterisation 
      of baseline levels of circulating full length and cleaved CK18 specifically in 
      patients with pancreatic cancer. METHODS: Plasma samples from 103 patients with 
      pancreatic cancer stored at -80 degrees C were assayed for M65 and M30 levels. 
      The median (inter-quartile range (IQR)) duration of plasma storage was 34 (23-57) 
      months. Patients with metastatic disease (n=19) were found to have greater median 
      (IQR) M65 levels (1145 (739-1698) U l(-1)) compared with the locally advanced 
      (n=20; 748 (406-1150) U l(-1)) and resected (n=64; 612 (331-987) U l(-1)) 
      patients (P=0.002). Elevated M65 levels were associated with poorer overall 
      survival on univariate (P<0.001) but not multivariate (P=0.202) analysis. M65 
      concentrations also exhibited significant associations with concurrent 
      serum-bilirubin levels (P<0.001) and the duration of plasma storage (P<0.001). 
      CONCLUSIONS: Baseline plasma CK18 levels in pancreatic cancer are affected by the 
      presence of obstructive jaundice and prolonged plasma storage. Clinical biomarker 
      studies utilising serial CK18 levels are warranted in pancreatic cancer, provided 
      consideration is given to these potentially confounding factors.
FAU - Dive, C
AU  - Dive C
AD  - Clinical and Experimental Pharmacology Group, Paterson Institute for Cancer 
      Research, University of Manchester, Manchester, UK.
FAU - Smith, R A
AU  - Smith RA
FAU - Garner, E
AU  - Garner E
FAU - Ward, T
AU  - Ward T
FAU - George-Smith, S St
AU  - George-Smith SS
FAU - Campbell, F
AU  - Campbell F
FAU - Greenhalf, W
AU  - Greenhalf W
FAU - Ghaneh, P
AU  - Ghaneh P
FAU - Neoptolemos, J P
AU  - Neoptolemos JP
LA  - eng
GR  - 08/29/02/DH_/Department of Health/United Kingdom
GR  - 11883/CRUK_/Cancer Research UK/United Kingdom
GR  - 8968/CRUK_/Cancer Research UK/United Kingdom
GR  - 1089464/CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100105
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CA-19-9 Antigen)
RN  - 0 (Keratin-18)
SB  - IM
MH  - Aged
MH  - Apoptosis
MH  - Biomarkers, Tumor/*blood
MH  - CA-19-9 Antigen/blood
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Keratin-18/*blood
MH  - Male
MH  - Middle Aged
MH  - Necrosis
MH  - Pancreatic Neoplasms/blood/*diagnosis/mortality
PMC - PMC2822934
EDAT- 2010/01/07 06:00
MHDA- 2010/02/24 06:00
PMCR- 2011/02/02
CRDT- 2010/01/07 06:00
PHST- 2010/01/07 06:00 [entrez]
PHST- 2010/01/07 06:00 [pubmed]
PHST- 2010/02/24 06:00 [medline]
PHST- 2011/02/02 00:00 [pmc-release]
AID - 6605494 [pii]
AID - 10.1038/sj.bjc.6605494 [doi]
PST - ppublish
SO  - Br J Cancer. 2010 Feb 2;102(3):577-82. doi: 10.1038/sj.bjc.6605494. Epub 2010 Jan 
      5.